-
Repro Med Systems (KRMD) Tops Q2 EPS by 3c ; Offers Guidance
-
KORU Medical names Adam Kalbermatten as chief commercial officer
-
KORU Medical Systems (KRMD) to Join Russell 3000 and Russell 2000 Indexes
-
Repro Med Systems (KRMD) Tops Q1 EPS by 3c, provides guidance
-
Repro Med Systems (KRMD) Tops Q4 EPS by 1c ; Offers Guidance
-
Piper Sandler Downgrades Koru Medical Systems Inc. (KRMD) to Neutral
-
Repro Med Systems (KRMD) Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology
-
Koru Medical Systems Inc. (KRMD) PT Raised to $6 at Craig-Hallum
-
Repro Med Systems (KRMD) Reports Prelim Q4 Results
-
Canaccord Genuity Reiterates Buy Rating on Koru Medical Systems Inc. (KRMD)
-
Repro Med Systems (KRMD) Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter
-
Koru Medical Systems Inc. (KRMD) PT Raised to $3.50 at Piper Sandler
-
Koru Medical Systems Inc. (KRMD) PT Raised to $4 at Canaccord Genuity
-
Repro Med Systems (KRMD) Tops Q3 EPS by 3c, provides guidance
-
Koru Medical Systems Inc. (KRMD) PT Raised to $3 at Piper Sandler
-
Canaccord Genuity Bullish on Koru Medical Systems Inc. (KRMD)

